CLRB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLRB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Cellectar Biosciences's Dividend Payout Ratio for the months ended in Sep. 2024 was 0.00.
The historical rank and industry rank for Cellectar Biosciences's Dividend Payout Ratio or its related term are showing as below:
As of today (2025-03-02), the Dividend Yield % of Cellectar Biosciences is 0.00%.
Cellectar Biosciences's Dividends per Share for the months ended in Sep. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
The historical data trend for Cellectar Biosciences's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Dividend Payout Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Cellectar Biosciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Dividend Payout Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Cellectar Biosciences's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Cellectar Biosciences's Dividend Payout Ratio falls into.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Cellectar Biosciences's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Dividend Payout Ratio | = | Dividends per Share (A: Dec. 2023 ) | / | EPS without NRI (A: Dec. 2023 ) |
= | 0 | / | -3.191 | |
= | N/A |
Cellectar Biosciences's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as
Dividend Payout Ratio | = | Dividends per Share (Q: Sep. 2024 ) | / | EPS without NRI (Q: Sep. 2024 ) |
= | 0 | / | -0.553 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences (NAS:CLRB) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of Cellectar Biosciences's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrei Shustov | officer: Senior Vice President, Medical | 7 PARKLAND DRIVE, MILFORD NJ 08848 |
Darrell Shane Lea | officer: Chief Commercial Officer | 7 PARKLAND DRIVE, MILFORD NJ 08848 |
Chad J Kolean | officer: Chief Financial Officer | C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716 |
Douglas J Swirsky | director | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850 |
Frederick W Driscoll | director | |
Asher Chanan-khan | director | C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932 |
James V Caruso | director, officer: President and CEO | C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562 |
Dov Elefant | officer: Chief Financial Officer | EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632 |
Jarrod Longcor | officer: Chief Business Officer | C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511 |
Friend John E. Ii | officer: VP, Chief Medical Officer | 26 ORCHARD LANE, COLT NECK NJ 07722 |
John Neis | director | 505 S. ROSA ROAD, SUITE 201, MADISON WI 53719 |
Stefan Loren | director | 3226 AVENIDA DE SUENO, CARLSBAD CA 92009 |
Stephen A Hill | director | 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999 |
Igor D Grachev | officer: Chief Medical Officer | 15 REID LANE, MILLSTONE TWP NJ 08535 |
Bernhardt Charles Thomas Iii | officer: Interim CFO | 23 BIRCH ROAD, MALVERN PA 19355 |
From GuruFocus
By Marketwired • 06-27-2024
By Marketwired • 08-26-2024
By GlobeNewswire • 11-01-2024
By GuruFocus News • 10-09-2024
By Marketwired • 08-13-2024
By Marketwired • 11-07-2024
By Marketwired • 11-14-2024
By Marketwired • 11-18-2024
By GuruFocus News • 11-19-2024
By GlobeNewswire • 12-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.